FDA Eases Rules for Breast Implant Retrieval System
Published Date: 6/26/2026
Rule
Summary
The FDA has officially placed the breast implant suction retrieval system into Class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps make the device safer and easier to get to patients without unnecessary delays. The new classification took effect on June 26, 2026, and could speed up innovation while keeping costs in check for makers and users.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Device moved to Class II — safer, more accessible
The FDA officially classified the breast implant suction retrieval system as Class II (special controls), effective June 26, 2026, with the classification applicable April 20, 2023. FDA says this classification provides reasonable assurance of safety and will enhance patients' access to beneficial innovation by reducing regulatory burdens compared with automatic Class III assignment.
Manufacturers must meet named special controls
Manufacturers of this prescription surgical device must meet specific special controls, including animal performance testing (showing removal of specified implant sizes and tissue healing assessment), non‑clinical performance testing (characterizing vacuum suction ranges, durability, and control/variation), sterility and shelf‑life testing, biocompatibility evaluation, usability testing, and labeling that lists vacuum pressure ranges, bottle capacity, and implant sizes/types. The device is subject to premarket notification under section 510(k) unless FDA later exempts it.
De Novo decision enables future 510(k) pathways
Because FDA classified the device via the De Novo process, the breast implant suction retrieval system can serve as a predicate for future devices of that type, allowing other sponsors to use the less‑burdensome 510(k) pathway rather than De Novo or PMA. FDA notes De Novo classification decisions are required to be issued in writing within 120 days of a request under the cited statutes.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19704, Robotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide for companies making robot-assisted surgical devices, showing how to get their products approved before selling. If you’re in the biz, now’s the time to check it out and send your feedback by November 24, 2026. This guide aims to make the approval process clearer and smoother, potentially saving time and money down the road.
2026-19655, Jeffrey Thies: Final Debarment Order
Jeffrey Thies is banned for 10 years from importing any drugs into the U.S. because he was convicted of trafficking fake drugs. He didn’t respond to the FDA’s notice, so the ban started on September 25, 2026. He can apply to end the ban anytime, but until then, no drug imports for him!
Previous / Next Documents
Previous: 2026-12902, Medical Devices; Immunology and Microbiology Devices; Classification of the SARS-CoV-2 Serology Test
The FDA is officially putting the COVID-19 antibody (serology) test into a safer, easier-to-manage category called Class II, starting June 26, 2026. This change helps make sure the tests work well and are safe, while also making it simpler for companies to bring new and better tests to patients. If you’re a test maker or user, expect smoother rules and better access without extra costs or delays.
Next: 2026-12904, Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs Syndrome
The FDA has officially placed the external lower leg nerve stimulator for Restless Legs Syndrome into a safer, easier-to-get category called Class II. This change helps patients get access to this helpful device faster while keeping safety in check. The new rules took effect on June 26, 2026, and could lower costs by cutting some red tape for makers and users alike.